The "Mad Money" host shares his earnings expectations for International Paper, Procter & Gamble and V.F. Corp.
The "Mad Money" host reveals his earnings expectations for Celgene, Exxon-Mobil, Amazon.com, Deckers Outdoor and Zynga.
John Lechleiter, Eli Lilly chairman & CEO breaks down his company's earnings results of an adjusted $0.92 a share versus estimates of $0.78 est. and a look at the drug maker's generic challenges, and the politics of prescriptions.
Vertex Pharmaceuticals is expected to report strong initial sales of its cystic fibrosis drug Kalydeco on Thursday as investors shift their attention away from the waning performance of the company's hepatitis C drug Incivek.
Amylin Pharmaceuticals, which spurned a $3.5 billion takeover bid from Bristol-Myers Squibb and is fending off a lawsuit from activist investor Carl Icahn, started reaching out to potential buyers last week, sources familiar with the situation said on Sunday.
A two-person surgical team has created a new, inexpensive bone-grafting device without having to go to big pharma.
Based on my discussions with several analysts, from reading their reports, I suspect that the earnings revisions occurred after the analysts had conversations with Mylan.
In 2011, Mylan’s longtime chief executive Robert Coury, who gave up the post at the end of the year to become executive chairman (he’s also chairman of the board) earned cash compensation of $7.4 million.
Investors can expect a muted first-quarter earnings season, and should add pharmaceutical stocks to their portfolios to guard against potentially rocky times ahead, according to investment bank UBS.
Shareholders of all girth face a host of meetings with the pharmaceutical company currently in the crosshairs of a hostile bid from Swiss drug maker Roche.
Johnson & Johnson said Tuesday that first-quarter profit jumped 12.5 percent as lower spending on research, sales and administration more than made up for a slight decrease in sales due to generic competition.
Why Amylin Pharmaceuticals shareholders should demand transparency and a public explanation of recent takeover talk.
The “Mad Money” host includes the drug company in his list of favorite growth names.
Mad Money's Cramer runs through a ten-point checklist to see if Celgene is in a position to deliver growth to investors.
Cramer's analysis on Allergan shows that it's a high-quality stock that can be bought into weakness.
The Spectrum Pharmaceuticals growth party is over.
Sharpen your pencils, it's Last Call quiz time.
Edward Perks, Senior Vice President, Franklin Templeton Investments, explains why he is moving away from long-duration fixed income and into equities with a focus on dividend plays.
CNBC's Seema Mody has the details on Regeneron Pharmaceuticals and Amgen releasing data on injectable drugs.
The promise of low-cost gene sequencing could lead to a new era of personalized medicine, yielding new approaches for treating cancers and other serious diseases. The New York Times reports.